在小鼠中,通过PPARγ参与的机制通过酸德克斯酸引起的性结肠炎对酸的预防作用
Guojiang Tian1, Fan Dong2, Ai Fu3
1Department of Anus and Colorectal Surgery, Shaoxing People's Hospital, Shaoxing, Zhejiang, People's Republic of China.
Drug design, development and therapy
|January 1, 2026
概括
醇酸 (OA) 通过稳定PPARγ,减少炎症和恢复肠道屏障功能,有效治疗性结肠炎 (UC). 这项研究揭示了OA通过PPARγ稳定在结肠炎中的机制.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 烯酸 (OA) 是一种天然的三烯酸,具有抗炎功能,但其在UC中的作用机制尚不清楚.
研究的目的:
- 为了研究酸 (OA) 的治疗效果和分子机制,在硫酸 (DSS) 诱导的急性结肠炎的小鼠模型中.
- 阐明OA在调节UC炎症通路和肠壁功能中的作用.
主要方法:
- 向患有DSS诱导的大肠炎的C57BL/6小鼠给予OA (25和50毫克/公斤/天).
- 评估临床症状,组织病理损伤,细胞因子概况,氧化应激标志物和肠道透性.
- 分析NF-κB信号通路激活和氧酶增殖器激活受体马 (PPARγ) 表达和稳定性的分析.
- 使用GW9662对PPARγ进行药理抑制,以确认其在OA保护作用中的作用.
主要成果:
- 甲状腺炎治疗显著降低了结肠炎的严重程度,包括体重减轻,结肠缩短和组织学损伤.
- 氨酸抑制了促炎性细胞因子,增强了抗炎性细胞因子,恢复了氧化还原平衡,并改善了肠道屏障完整性.
- 通过稳定PPARγ,OA抑制了NF-κB激活,这对其保护作用至关重要,正如GW9662治疗所证明的那样.
结论:
- 醇酸 (OA) 通过减少炎症和恢复肠道屏障功能,显示出性结肠炎 (UC) 的显著治疗潜力.
- 氨酸通过一种新的机制发挥其保护作用,包括PPARγ的翻译后稳定,从而抑制NF-κB激活.
- 这项研究为肠道炎症中核受体调节提供了关键的机制性见解,并强调OA是UC的有前途的治疗剂.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
815
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
815
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K


